Bringing a New Modality to Scale w/John Maraganore, Alnylam (mod. Jennifer Wipf)  

John Maraganore, PhD, In conversation with Jennifer Wipf
Cell and gene therapy breakthroughs now offer promise to patients with intractable diseases. Patients need access to these novel approaches - but introducing new modalities is incredibly challenging to pharmaceutical companies due to technical, regulatory, and commercial risks. Alnylam founder John Maraganore navigated this complexity when bringing siRNA therapeutics from the lab to patients. In this fireside chat, John offers his insights to companies that are bringing new technologies to scale.
www.ginkgoferm...